Table 2.
CVD risk factor prevalence and control, compared between NHB and NHW adult kidney transplant recipients
| CVD Variable | Baseline | One Year | Three Years | Five Years | ||||
|---|---|---|---|---|---|---|---|---|
| NHW | NHB | NHW | NHB | NHW | NHB | NHW | NHB | |
| Prevalence of Hypertension† | 92.3% | 96.4%‡ | 97.2% | 99.0%‡ | 98.7% | 99.9%‡ | 99.2% | 100.0%‡ |
| Prevalence of Diabetes§ | 38.4% | 38.8% | 46.9% | 50.3% | 49.4% | 52.9% | 53.3% | 58.9%‡ |
| Prevalence of Dyslipidemia‖ | 46.4% | 40.7%‡ | 69.2% | 63.3%‡ | 81.4% | 77.2%‡ | 86.3% | 83.9% |
| Mean Systolic BP (±SD) | 140±18 | 141±19 | 137±14 | 139±15‡ | 136±12 | 138±12* | 135±11 | 137±12‡ |
| Mean Diastolic BP (±SD) | 75±10 | 79±11‡ | 73±9 | 76±9‡ | 73±8 | 76±8‡ | 73±8 | 77±8‡ |
| Blood Pressure <140/90 mmHg | 51% | 46%* | 60% | 52%‡ | 65% | 58%‡ | 69% | 60%‡ |
| Mean Hemoglobin A1c (±SD) | 6.6±1.3 | 6.5±1.5 | 7.1±1. | 7.8±1.7‡ | 7.2±1.3 | 7.8±1.6‡ | 7.2±1.2 | 7.7±1.6‡ |
| Hemoglobin A1c <7%¶ | 57% | 61% | 53% | 35%‡ | 46% | 31%‡ | 47% | 35%‡ |
| Hemoglobin A1c <8%¶ | 92% | 93% | 87% | 78%‡ | 83% | 74%‡ | 86% | 83% |
| Mean LDL (±SD) | 86±32 | 86±31 | 100±34 | 103±34 | 97±30 | 102±32‡ | 95±28 | 99±30‡ |
| LDL <100 mg/dL | 72% | 70% | 52% | 51% | 56% | 52%* | 61% | 55%‡ |
| Mean TG (±SD) | 200±149 | 164±105‡ | 198±150 | 161±104‡ | 194±126 | 160±98‡ | 187±120 | 154±86‡ |
| TG < 150 mg/dL | 46% | 57%‡ | 44% | 59%‡ | 43% | 57%‡ | 45% | 60%‡ |
| Prescribed ACE inhibitor or ARB# | 48% | 50% | 35% | 38%* | 50% | 54%* | 56% | 61%‡ |
| MPR ≥80% | 23% | 18%* | 56% | 49%* | 53% | 51% | 52% | 40%‡ |
| Prescribed Beta Blocker# | 49% | 51% | 59% | 64%* | 70% | 73%* | 73% | 78%* |
| MPR ≥80% | 34% | 23%‡ | 61% | 56%* | 56% | 47%‡ | 51% | 46% |
| Prescribed Oral Anti-hyperglycemic¶ | 34% | 35% | 30% | 33% | 36% | 38% | 39% | 42% |
| MPR ≥80% | 17% | 19% | 60% | 49%* | 44% | 47% | 49% | 43% |
| Prescribed Insulin¶ | 48% | 44% | 62% | 66% | 70% | 73% | 70% | 74% |
| MPR ≥80% | 69% | 45%‡ | 86% | 78%‡ | 83% | 82% | 84% | 76%* |
| Prescribed Statin** | 84% | 80%* | 74% | 70% | 77% | 76% | 78% | 78% |
| MPR ≥80% | 37% | 22%‡ | 62% | 52%‡ | 57% | 50%* | 58% | 43%‡ |
| Prescribed Other Anti-Lipemic** | 19% | 17% | 13% | 7%‡ | 19% | 12%‡ | 20% | 12%‡ |
| MPR ≥80% | 18% | 7%‡ | 58% | 60% | 46% | 43% | 51% | 40% |
| Prescribed Anti-platelet | 10% | 7%‡ | 7% | 5% | 10% | 7%‡ | 13% | 9%‡ |
| MPR ≥80% | 27% | 21% | 51% | 42% | 51% | 35%* | 44% | 24% |
*
p<0.05
‡
p<0.01
†
Defined as documentation, blood pressure >140/90 mmHg or treatment with anti-hypertensive therapy
§
Defined as documentation, hemoglobin A1c >7% or treatment with anti-glycemic therapy
‖
Defined as a LDL >130 mg/dL, TG >150 mg/dL or treatment with anti-lipemic therapy
¶
Only in those with a diagnosis of diabetes
#
Only in those with a diagnosis of hypertension
**
Only in those with a diagnosis of dyslipidemia